Nexentis Technologies Inc. (NXTS)
NASDAQ: NXTS · Real-Time Price · USD
4.735
-0.105 (-2.17%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Nexentis Technologies Revenue
Nexentis Technologies had revenue of $-68.00K in the quarter ending December 31, 2025, a decrease of -1.45%.
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
3.46M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nutrien | 25.95B |
| The Mosaic Company | 12.05B |
| ICL Group | 7.15B |
| CF Industries Holdings | 7.08B |
| FMC Corporation | 3.47B |
| The Scotts Miracle-Gro Company | 3.40B |
| CVR Partners | 606.04M |
| American Vanguard | 515.11M |
NXTS News
- 2 months ago - N2OFF, Inc. Provides Early Warning Disclosure - TheNewswire
- 3 months ago - In Spaceflight Conditions: N2OFF‘s MitoCareX Bio Highlights Co-Founder's Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation Conditions - GlobeNewsWire
- 3 months ago - N2OFF: MitoCareX Bio Announces Positive In Vitro Results from Its Mitochondrial Carrier Small Molecule Platform - GlobeNewsWire
- 3 months ago - N2OFF: MitoCareX Bio Spotlights Co-Founder's Pioneering Research on Mitochondrial Carriers in Spaceflight Stress Conditions - GlobeNewsWire
- 4 months ago - N2OFF Advances $340,000 Payment to Gain Better Terms in Flag Solar Energy Initiative, Reflecting Approximately an Additional $1.7 Million in Project Profit Stake - GlobeNewsWire
- 4 months ago - N2OFF Accelerates European Renewable Energy Momentum with Major De-Risking Milestones and Approximately $1.69 Million Value Unlock in Germany and Italy - GlobeNewsWire
- 5 months ago - N2OFF: MitoCareX Identifies Hit Compounds and Targets Preclinical Candidate Nomination - GlobeNewsWire
- 6 months ago - N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers - GlobeNewsWire